Anti-proliferative and pro-apoptotic effects of lichen-derived compound protolichesterinic acid are not mediated by its lipoxygenase-inhibitory activity

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 98, Issue , 2015, Pages 39-47

  Bessadottir M ^a,b   Eiriksson F F ^a,b   Becker, S ^a   Ogmundsdottir M H ^a   Omarsdottir S ^b   Thorsteinsdottir M ^b   Ogmundsdottir H M ^a  

^a UNIVERSITY OF ICELAND   (Iceland)

^b UNIVERSITY OF ICELAND   (Iceland)

Author keywords

Cancer; Lipoxygenase; Mass spectrometry; Protolichesterinic acid

Indexed keywords

ARACHIDONATE 12 LIPOXYGENASE; ARACHIDONATE 5 LIPOXYGENASE; LIPOXYGENASE INHIBITOR; NATURAL PRODUCT; PLACEBO; PROTOLICHESTERINIC ACID; UNCLASSIFIED DRUG; ALOX12 PROTEIN, HUMAN; ALOX5 PROTEIN, HUMAN; GAMMA BUTYROLACTONE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL LEVEL; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG ISOLATION; DRUG MECHANISM; DRUG TARGETING; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC50; LICHEN (ORGANISM); MULTIPLE MYELOMA CELL LINE; NONHUMAN; PANCREATIC CANCER CELL LINE; PRIORITY JOURNAL; PROTEIN DETERMINATION; ANALOGS AND DERIVATIVES; CHEMISTRY; CYTOPLASM; DOSE RESPONSE; DRUG EFFECTS; ENZYMOLOGY; GENE EXPRESSION REGULATION; METABOLISM; MULTIPLE MYELOMA; PANCREATIC NEOPLASMS; TUMOR CELL LINE;

4-BUTYROLACTONE; APOPTOSIS; ARACHIDONATE 12-LIPOXYGENASE; ARACHIDONATE 5-LIPOXYGENASE; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOPLASM; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LICHENS; MULTIPLE MYELOMA; PANCREATIC NEOPLASMS;

EID: 84929709287     PISSN: 09523278     EISSN: 15322823     Source Type: Journal    
DOI: 10.1016/j.plefa.2015.04.009     Document Type: Article

References (48)

1. Pidgeon G.P., Lysaght J., Krishnamoorthy S., et al. Lipoxygenase metabolism: roles in tumor progression and survival. Cancer Metastasis Rev. 2007, 26:503-524.
2. Schneider C., Pozzi A. Cyclooxygenases and lipoxygenases in cancer. Cancer Metastasis Rev. 2011, 30:277-294.
3. Cathcart M.C., Lysaght J., Pidgeon G.P. Eicosanoid signalling pathways in the development and progression of colorectal cancer: novel approaches for prevention/intervention. Cancer Metastasis Rev. 2011, 30:363-385.
4. Wang D., Dubois R.N. Eicosanoids and cancer. Nat. Rev. Cancer 2010, 10:181-193.
5. Panigrahy D., Kaipainen A., Greene E.R., Huang S. Cytochrome P450-derived eicosanoids: the neglected pathway in cancer. Cancer Metastasis Rev. 2010, 29:723-735.
6. Fenn J.B., Mann M., Meng C.K., Wong S.F., Whitehouse C.M. Electrospray ionization for mass spectrometry of large biomolecules. Science 1989, 246:64-71.
7. Murphy R.C., Gaskell S.J. New applications of mass spectrometry in lipid analysis. J. Biol. Chem. 2011, 286:25427-25433.
8. Ohd J.F., Nielsen C.K., Campbell J., Landberg G., Lofberg H., Sjolander A. Expression of the leukotriene D4 receptor CysLT1, COX-2, and other cell survival factors in colorectal adenocarcinomas. Gastroenterology 2003, 124:57-70.
9. Gupta S., Srivastava M., Ahmad N., Sakamoto K., Bostwick D.G., Mukhtar H. Lipoxygenase-5 is overexpressed in prostate adenocarcinoma. Cancer 2001, 91:737-743.
10. Chen X., Wang S., Wu N., et al. Overexpression of 5-lipoxygenase in rat and human esophageal adenocarcinoma and inhibitory effects of zileuton and celecoxib on carcinogenesis. Clin. Cancer Res. 2004, 10:6703-6709.
11. Jiang W.G., Douglas-Jones A., Mansel R.E. Levels of expression of lipoxygenases and cyclooxygenase-2 in human breast cancer. Prostaglandins Leukot Essent. Fatty Acids 2003, 69:275-281.
12. Hennig R., Ding X.Z., Tong W.G., et al. 5-Lipoxygenase and leukotriene B(4) receptor are expressed in human pancreatic cancers but not in pancreatic ducts in normal tissue. Am. J. Pathol. 2002, 161:421-428.
13. Ding X.Z., Hennig R., Adrian T.E. Lipoxygenase and cyclooxygenase metabolism: new insights in treatment and chemoprevention of pancreatic cancer. Mol. Cancer 2003, 2:10.
14. Ferry D.R., Deakin M., Baddeley J., et al. A phase II study of the 5-lipoxygenase inhibitor, CV6504, in advanced pancreatic cancer: correlation of clinical data with pharmacokinetic and pharmacodynamic endpoints. Ann. Oncol. 2000, 11:1165-1170.
15. Anderson K.M., Seed T., Jajeh A., et al. An in vivo inhibitor of 5-lipoxygenase, MK886, at micromolar concentration induces apoptosis in U937 and CML cells. Anticancer Res. 1996, 16:2589-2599.
16. Anderson K.M., Rubenstein M., Tsui P., Harris J.E. Disparate forms of MK 886-induced programmed death in BCL-2 (+) blood and BCL-2 (-) solid cancer cells and a putative nuclear Ca2+ channel: soil trumps seed?. Med. Hypotheses 2005, 64:307-311.
17. Aparoy P., Reddy K.K., Reddanna P. Structure and ligand based drug design strategies in the development of novel 5- LOX inhibitors. Curr. Med. Chem. 2012, 19:3763-3778.
18. Drazen J.M., Israel E., O'Byrne P.M. Treatment of asthma with drugs modifying the leukotriene pathway. N. Engl. J. Med. 1999, 340:197-206.
19. Li N., Sood S., Wang S., et al. Overexpression of 5-lipoxygenase and cyclooxygenase 2 in hamster and human oral cancer and chemopreventive effects of zileuton and celecoxib. Clin. Cancer Res. 2005, 11:2089-2096.
20. Fischer A.S., Metzner J., Steinbrink S.D., et al. 5-Lipoxygenase inhibitors induce potent anti-proliferative and cytotoxic effects in human tumour cells independently of suppression of 5-lipoxygenase activity. Br. J. Pharmacol. 2010, 161:936-949.
21. Pidgeon G.P., Kandouz M., Meram A., Honn K.V. Mechanisms controlling cell cycle arrest and induction of apoptosis after 12-lipoxygenase inhibition in prostate cancer cells. Cancer Res. 2002, 62:2721-2727.
22. Tong W.G., Ding X.Z., Witt R.C., Adrian T.E. Lipoxygenase inhibitors attenuate growth of human pancreatic cancer xenografts and induce apoptosis through the mitochondrial pathway. Mol. Cancer Ther. 2002, 1:929-935.
23. Ingolfsdottir K., Breu W., Huneck S., Gudjonsdottir G.A., Muller-Jakic B., Wagner H. In vitro inhibition of 5-lipoxygenase by protolichesterinic acid from Cetraria islandica. Phytomedicine 1994, 1:187-191.
24. Ingolfsdottir K., Gissurarson S.R., Muller-Jakic B., Breu W., Wagner H. Inhibitory effects of the lichen metabolite lobaric acid on arachidonate metabolism in vitro. Phytomedicine 1996, 2:243-246.
25. Bucar F., Schneider I., Ogmundsdottir H., Ingolfsdottir K. Anti-proliferative lichen compounds with inhibitory activity on 12(S)-HETE production in human platelets. Phytomedicine 2004, 11:602-606.
26. Haraldsdottir S., Guolaugsdottir E., Ingolfsdottir K., Ogmundsdottir H.M. Anti-proliferative effects of lichen-derived lipoxygenase inhibitors on twelve human cancer cell lines of different tissue origin in vitro. Planta Med. 2004, 70:1098-1100.
27. Ogmundsdottir H.M., Zoega G.M., Gissurarson S.R., Ingolfsdottir K. Anti-proliferative effects of lichen-derived inhibitors of 5-lipoxygenase on malignant cell-lines and mitogen-stimulated lymphocytes. J. Pharm. Pharmacol. 1998, 50:107-115.
28. Bessadottir M., Skuladottir E.A., Gowan S., Eccles S., Omarsdottir S., Ogmundsdottir H.M. Effects of anti-proliferative lichen metabolite, protolichesterinic acid on fatty acid synthase, cell signalling and drug response in breast cancer cells. Phytomedicine 2014, 21:1717-1724.
29. Funk C.D. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 2001, 294:1871-1875.
30. Jakobsson P.J., Steinhilber D., Odlander B., Radmark O., Claesson H.E., Samuelsson B. On the expression and regulation of 5-lipoxygenase in human lymphocytes. Proc. Natl. Acad. Sci. U.S.A. 1992, 89:3521-3525.
31. Ding X.Z., Iversen P., Cluck M.W., Knezetic J.A., Adrian T.E. Lipoxygenase inhibitors abolish proliferation of human pancreatic cancer cells. Biochem. Biophys. Res. Commun. 1999, 261:218-223.
32. Carter G.W., Young P.R., Albert D.H., et al. 5-Lipoxygenase inhibitory activity of zileuton. J. Pharmacol. Exp. Ther. 1991, 256:929-937.
33. Brisdelli F., Perilli M., Sellitri D., et al. Cytotoxic activity and antioxidant capacity of purified lichen metabolites: an in vitro study. Phytother. Res. 2013, 27:431-437.
34. Leslie C.C. Regulation of arachidonic acid availability for eicosanoid production. Biochem. Cell Biol. 2004, 82:1-17.
35. Peters-Golden M. Cell biology of the 5-lipoxygenase pathway. Am. J. Respir. Crit. Care Med. 1998, 157:S227-S232.
36. Flamand N., Luo M., Peters-Golden M., Brock T.G. Phosphorylation of serine 271 on 5-lipoxygenase and its role in nuclear export. J. Biol. Chem. 2009, 284:306-313.
37. Hussey H.J., Tisdale M.J. Inhibition of tumour growth by lipoxygenase inhibitors. Br. J. Cancer 1996, 74:683-687.
38. Rossi A., Pergola C., Koeberle A., et al. The 5-lipoxygenase inhibitor, zileuton, suppresses prostaglandin biosynthesis by inhibition of arachidonic acid release in macrophages. Br. J. Pharmacol. 2010, 161:555-570.
39. Cianchi F., Cortesini C., Magnelli L., et al. Inhibition of 5-lipoxygenase by MK886 augments the antitumor activity of celecoxib in human colon cancer cells. Mol. Cancer Ther. 2006, 5:2716-2726.
40. Avis I., Martinez A., Tauler J., et al. Inhibitors of the arachidonic acid pathway and peroxisome proliferator-activated receptor ligands have superadditive effects on lung cancer growth inhibition. Cancer Res. 2005, 65:4181-4190.
41. Hennig R., Grippo P., Ding X.Z., et al. 5-Lipoxygenase, a marker for early pancreatic intraepithelial neoplastic lesions. Cancer Res. 2005, 65:6011-6016.
42. Sabirsh A., Bristulf J., Karlsson U., Owman C., Haeggstrom J.Z. Non-specific effects of leukotriene synthesis inhibitors on HeLa cell physiology. Prostaglandins Leukot Essent. Fatty Acids 2005, 73:431-440.
43. Deschamps J.D., Kenyon V.A., Holman T.R. Baicalein is a potent in vitro inhibitor against both reticulocyte 15-human and platelet 12-human lipoxygenases. Bioorg. Med. Chem. 2006, 14:4295-4301.
44. Aggarwal B.B., Bhardwaj A., Aggarwal R.S., Seeram N.P., Shishodia S., Takada Y. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res. 2004, 24:2783-2840.
45. He S., Yan X. From resveratrol to its derivatives: new sources of natural antioxidant. Curr. Med. Chem. 2013, 20:1005-1017.
46. Kurita T., Makino Y. Novel curcumin oral delivery systems. Anticancer Res. 2013, 33:2807-2821.
47. Al-Shabrawey M., Mussell R., Kahook K., et al. Increased expression and activity of 12-lipoxygenase in oxygen-induced ischemic retinopathy and proliferative diabetic retinopathy: implications in retinal neovascularization. Diabetes 2011, 60:614-624.
48. Gilbert N.C., Bartlett S.G., Waight M.T., et al. The structure of human 5-lipoxygenase. Science 2011, 331:217-219.